tetano
Editor, Senior Moderator
Vaccine
. 2022 Apr 23;S0264-410X(22)00489-3.
doi: 10.1016/j.vaccine.2022.04.049. Online ahead of print.
Clinical relevance of increased antibody titres in older adults upon vaccination with squalene-adjuvanted versus non-adjuvanted influenza vaccines
Walter E P Beyer[SUP] 1 [/SUP], Abraham M Palache[SUP] 2 [/SUP], Mimoun Boulfich[SUP] 3 [/SUP], Albert D M E Osterhaus[SUP] 4 [/SUP]
Affiliations
Abstract
In older adults, the serum antibody response to inactivated influenza vaccine (IIV) is often lower than in adolescents and non-elderly adults which may translate into suboptimal protection against influenza. To counteract this expression of immunosenescence, the use of adjuvanted IIV formulations has been explored. Four recent studies (three meta-analyses and one clinical trial) found an antibody increase of up to 1.5-fold in older adults, when a squalene-adjuvanted (MF59™) IIV was used. The clinical relevance of this increase may well continue to be a matter of debate. We would favour a threshold of 1.5 to consider an adjuvanted vaccine formulation superior to standard aqueous IIV because it exceeds the inevitable variation of antibody responses to non-adjuvanted IIV. It is also the same as the upper FDA equivalence limit for IIV lot-to-lot consistency. A corresponding threshold for the seroresponse rate difference could then be +5%.
Keywords: Adjuvant; Clinical relevance; Immunogenicity; Influenza vaccine.
. 2022 Apr 23;S0264-410X(22)00489-3.
doi: 10.1016/j.vaccine.2022.04.049. Online ahead of print.
Clinical relevance of increased antibody titres in older adults upon vaccination with squalene-adjuvanted versus non-adjuvanted influenza vaccines
Walter E P Beyer[SUP] 1 [/SUP], Abraham M Palache[SUP] 2 [/SUP], Mimoun Boulfich[SUP] 3 [/SUP], Albert D M E Osterhaus[SUP] 4 [/SUP]
Affiliations
- PMID: 35473661
- DOI: 10.1016/j.vaccine.2022.04.049
Abstract
In older adults, the serum antibody response to inactivated influenza vaccine (IIV) is often lower than in adolescents and non-elderly adults which may translate into suboptimal protection against influenza. To counteract this expression of immunosenescence, the use of adjuvanted IIV formulations has been explored. Four recent studies (three meta-analyses and one clinical trial) found an antibody increase of up to 1.5-fold in older adults, when a squalene-adjuvanted (MF59™) IIV was used. The clinical relevance of this increase may well continue to be a matter of debate. We would favour a threshold of 1.5 to consider an adjuvanted vaccine formulation superior to standard aqueous IIV because it exceeds the inevitable variation of antibody responses to non-adjuvanted IIV. It is also the same as the upper FDA equivalence limit for IIV lot-to-lot consistency. A corresponding threshold for the seroresponse rate difference could then be +5%.
Keywords: Adjuvant; Clinical relevance; Immunogenicity; Influenza vaccine.